Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits
- 15 January 2007
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (2) , 414-418
- https://doi.org/10.1016/j.bmcl.2006.10.028
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisNew England Journal of Medicine, 2006
- Drug discovery: selecting the optimal approachDrug Discovery Today, 2006
- Neuroinflammation: a potential therapeutic targetEmerging Therapeutic Targets, 2005
- Glia and their cytokines in progression of neurodegenerationPublished by Elsevier ,2004
- Epilepsy after head injuryCurrent Opinion in Neurology, 2004
- Anti-TNF- therapies: they are all the same (aren't they?)Rheumatology, 2004
- GLIA: A novel drug discovery target for clinical painNature Reviews Drug Discovery, 2003
- Molecular Properties That Influence the Oral Bioavailability of Drug CandidatesJournal of Medicinal Chemistry, 2002
- Anti-Cytokine Therapy for Rheumatoid ArthritisAnnual Review of Medicine, 2000
- 3-Aminopyridazine derivatives with atypical antidepressant, serotonergic and dopaminergic activitiesJournal of Medicinal Chemistry, 1989